Targets › MMAE
1 program from 1 company in 1 trial: 1 Phase 1; Oncology.
Open in Phaseline: the race on MMAE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhejiang Teruisi Pharmaceutical | TRS005 Anti-CD20 monoclonal antibody-MMAE antibody-drug conjugate | CD20, MMAE | Phase 1 | CD20-positive B-cell Non-Hodgkin Lymphoma | – |
CD20-positive B-cell Non-Hodgkin Lymphoma (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.